New CAR-T therapy targets two proteins to fight tough leukemia and lymphoma

NCT ID NCT06879262

Not yet recruiting Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD22) on cancer cells. It is for people with relapsed or refractory B-cell acute lymphoblastic leukemia or non-Hodgkin lymphoma. Participants receive a single infusion of these modified immune cells and are followed for three years to check safety and response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CAR1922T2 T cells (a type of immune cell therapy that targets two proteins on cancer cells)
What this could lead to: If successful, this could offer a new treatment option for people with hard-to-treat B-cell cancers that have not responded to standard therapies.
What could go wrong: This is a very early (Phase 1) trial with only 60 participants, so safety and effectiveness are not yet proven. CAR-T therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for R/R NHL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

R/R NHL

More trials for these conditions

Other studies related to the condition(s) this trial covers.